CDX-011 Shows Promise in Advanced Breast Cancer Ailment
According to a new research report by RNCOS entitled, "Global Antibody Drug Conjugate Market Outlook 2018", CDX-011 is a fully human monoclonal antibody drug conjugate targeting glycoprotein non-metastatic b (GPNMB) protein. GPNMB is expressed by multiple tumor types including breast cancer and melanoma. This antibody candidate is linked to potent cytotoxic monomethyl auristatin E using Seattle's genetic proprietary technology. In 2013, Celldex Therapeutics launched a METRIC study of CDX-011 in patients with metastatic triple negative breast cancer with over expressed...
View full press release